Literature DB >> 15009458

Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).

A Veyradier1, J-M Lavergne, A-S Ribba, B Obert, C Loirat, D Meyer, J-P Girma.   

Abstract

ADAMTS13, the specific von Willebrand factor (VWF)-cleaving metalloprotease, prevents the spontaneous formation of platelet thrombi in the microcirculation by degrading the highly adhesive ultralarge VWF multimers into smaller forms. ADAMTS13 severe enzymatic deficiency and mutations have been described in the congenital thrombotic thrombocytopenic purpura (TTP or Upshaw-Schulman syndrome), a rare and severe disease related to multivisceral microvascular thrombosis. We investigated six French families with congenital TTP for ADAMTS13 enzymatic activity and gene mutations. Six probands with congenital TTP and their family were tested for ADAMTS13 activity in plasma using a two-site immunoradiometric assay and for ADAMTS13 gene mutations using polymerase chain reaction and sequencing. ADAMTS13 activity was severely deficient (< 5%) in the six probands and one mildly symptomatic sibling but normal (> 50%) in all the parents and the asymptomatic siblings. Ten novel candidate ADAMTS13 mutations were identified in all families, showing either a compound heterozygous or a homozygous status in all probands plus the previous sibling and a heterozygous status in the parents. The mutations were spread all over the gene, involving the metalloprotease domain (I79M, S203P, R268P), the disintegrin domain (29 bp deletion in intron/exon 8), the cystein-rich domain (acceptor splice exon 12, R507Q), the spacer domain (A596V), the 3rd TSP1 repeat (C758R), the 5th TSP1 repeat (C908S) and the 8th TSP1 repeat (R1096stop). This study emphasizes the role of ADAMTS13 mutations in the pathogenesis of congenital TTP and suggests that several structural domains of this metalloprotease are involved in both its biogenesis and its substrate recognition process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009458     DOI: 10.1111/j.1538-7933.2004.00623.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  21 in total

Review 1.  Extracellular matrix proteins in hemostasis and thrombosis.

Authors:  Wolfgang Bergmeier; Richard O Hynes
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

Review 2.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

3.  Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.

Authors:  David G Motto; Anil K Chauhan; Guojing Zhu; Jonathon Homeister; Colin B Lamb; Karl C Desch; Weirui Zhang; Han-Mou Tsai; Denisa D Wagner; David Ginsburg
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

4.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Paul Knöbl; Karim Kentouche; Lawrence Rice; Jerzy Windyga; Reinhard Schneppenheim; Johanna A Kremer Hovinga; Michiko Kajiwara; Yoshihiro Fujimura; Caterina Maggiore; Jennifer Doralt; Christopher Hibbard; Leah Martell; Bruce Ewenstein
Journal:  Blood       Date:  2017-09-14       Impact factor: 22.113

Review 5.  Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.

Authors:  Suresh G Shelat; Jihui Ai; X Long Zheng
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

Review 6.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 7.  Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

Review 8.  The kidney in thrombotic thrombocytopenic purpura.

Authors:  H-M Tsai
Journal:  Minerva Med       Date:  2007-12       Impact factor: 4.806

Review 9.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

Authors:  Chantal Loirat; Jean-Pierre Girma; Céline Desconclois; Paul Coppo; Agnès Veyradier
Journal:  Pediatr Nephrol       Date:  2008-06-24       Impact factor: 3.714

10.  The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.

Authors:  Roberta Palla; Silvia Lavoretano; Rossana Lombardi; Isabella Garagiola; Mehran Karimi; Abdolreza Afrasiabi; Mani Ramzi; Raimondo De Cristofaro; Flora Peyvandi
Journal:  Haematologica       Date:  2008-12-30       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.